Livzon Pharmaceutical Secures Licensing Agreement for LanssonPharm’s PDE4 Inhibitor in China
China-based Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced a significant licensing agreement...
LanssonPharm
LanssonPharm’s Anti-Depression Drug LS21031 Receives CDE Approval for Clinical Trials
China-based central nervous system (CNS) drug developer LanssonPharm has announced that it has received clinical...
LanssonPharm Secures Series A Funding to Accelerate CNS Drug Development
LanssonPharm, a company dedicated to the development of central nervous system (CNS) drugs, has announced...